Givaudan (GVDBF) Given Average Rating of “Hold” by Analysts

Shares of Givaudan (OTCMKTS:GVDBF) have received a consensus rating of “Hold” from the eight analysts that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company.

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Givaudan in a report on Monday, March 12th. Barclays reaffirmed a “sell” rating on shares of Givaudan in a report on Wednesday, February 28th. UBS reaffirmed a “neutral” rating on shares of Givaudan in a report on Monday, February 5th. Citigroup reaffirmed a “sell” rating on shares of Givaudan in a report on Tuesday, January 30th. Finally, Deutsche Bank reaffirmed a “neutral” rating on shares of Givaudan in a report on Tuesday, January 30th.

Shares of Givaudan (OTCMKTS GVDBF) traded up $35.08 during trading hours on Tuesday, hitting $2,275.53. 24 shares of the stock traded hands, compared to its average volume of 96. Givaudan has a twelve month low of $1,785.08 and a twelve month high of $2,395.76.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3300327/givaudan-gvdbf-given-average-rating-of-hold-by-analysts.html.

Givaudan Company Profile

Analyst Recommendations for Givaudan (OTCMKTS:GVDBF)

Receive News & Ratings for Givaudan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Givaudan and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Comparison: Pure Bioscience  versus Platform Specialty Products
Critical Comparison: Pure Bioscience versus Platform Specialty Products
Global Power Equipment Gr  versus Mobile Mini  Head-To-Head Analysis
Global Power Equipment Gr versus Mobile Mini Head-To-Head Analysis
Q3 2018 EPS Estimates for CoStar Group  Lifted by B. Riley
Q3 2018 EPS Estimates for CoStar Group Lifted by B. Riley
Q3 2018 Earnings Estimate for Alphabet Inc. Issued By William Blair
Q3 2018 Earnings Estimate for Alphabet Inc. Issued By William Blair
$682.20 Million in Sales Expected for Genpact  This Quarter
$682.20 Million in Sales Expected for Genpact This Quarter
SunTrust Banks Analysts Lift Earnings Estimates for The Coca-Cola Company
SunTrust Banks Analysts Lift Earnings Estimates for The Coca-Cola Company


© 2006-2018 Ticker Report. Google+.